Robert Chan

2.0k total citations
46 papers, 706 citations indexed

About

Robert Chan is a scholar working on Physiology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Chan has authored 46 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Physiology, 18 papers in Otorhinolaryngology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Chan's work include Asthma and respiratory diseases (22 papers), Sinusitis and nasal conditions (18 papers) and Allergic Rhinitis and Sensitization (16 papers). Robert Chan is often cited by papers focused on Asthma and respiratory diseases (22 papers), Sinusitis and nasal conditions (18 papers) and Allergic Rhinitis and Sensitization (16 papers). Robert Chan collaborates with scholars based in United States, United Kingdom and Germany. Robert Chan's co-authors include Ana R. Sousa, Joseph K. Han, Steven G. Smith, Claus Bachert, Henrik Watz, Helen Barnacle, Benjamin Hartley, Peter Howarth, Steven W. Yancey and Bhabita Mayer and has published in prestigious journals such as Circulation, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Robert Chan

43 papers receiving 690 citations

Peers

Robert Chan
Alessandro Milani Italy
Ming‐Hsien Tsai Taiwan
S.C. Erzurum United States
A.J. Staal-van den Brekel Netherlands
Alexander Nixon United States
Hela Ben Nasr Tunisia
Sema Uysal Türkiye
Liyuan Zhang China
Hai‐Jeon Yoon South Korea
Alessandro Milani Italy
Robert Chan
Citations per year, relative to Robert Chan Robert Chan (= 1×) peers Alessandro Milani

Countries citing papers authored by Robert Chan

Since Specialization
Citations

This map shows the geographic impact of Robert Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Chan more than expected).

Fields of papers citing papers by Robert Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Chan. The network helps show where Robert Chan may publish in the future.

Co-authorship network of co-authors of Robert Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Chan. A scholar is included among the top collaborators of Robert Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Chan. Robert Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pfaar, Oliver, Anju T. Peters, Camille Taillé, et al.. (2025). Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach. Clinical and Translational Allergy. 15(1). e70010–e70010. 3 indexed citations
2.
Pavord, Ian, D.J. Jackson, Stephanie Korn, et al.. (2024). Clinical trial design of biologic therapies in COPD: MATINEE study of mepolizumab. PA4789–PA4789. 1 indexed citations
3.
Chen, Ruchong, Liping Wei, Danrong Yang, et al.. (2024). Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial. ERJ Open Research. 10(3). 750–2023. 6 indexed citations
4.
Desrosiers, Martin, Zuzana Diamant, Paolo Castelnuovo, et al.. (2023). Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up. International Forum of Allergy & Rhinology. 14(1). 18–31. 19 indexed citations
5.
Chupp, Geoffrey, Isam Alobid, Njira Lugogo, et al.. (2023). Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal of Allergy and Clinical Immunology In Practice. 11(11). 3504–3512.e2. 11 indexed citations
6.
Bachert, Claus, Amber Luong, Philippe Gevaert, et al.. (2023). The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti–IL-5 Biologic Therapy. The Journal of Allergy and Clinical Immunology In Practice. 11(9). 2630–2641. 20 indexed citations
7.
Gevaert, Philippe, Joseph K. Han, Steven G. Smith, et al.. (2022). The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology. 12(11). 1413–1423. 73 indexed citations
8.
Borish, Larry, Noah Cohen, Geoffrey Chupp, et al.. (2022). Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. Annals of Allergy Asthma & Immunology. 129(2). 160–168. 17 indexed citations
9.
Fokkens, Wytske J., Joaquim Mullol, David W. Kennedy, et al.. (2022). Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In‐depth sinus surgery analysis. Allergy. 78(3). 812–821. 24 indexed citations
10.
Hopkins, Claire, Claus Bachert, Martin Desrosiers, et al.. (2021). Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study. Pneumologie. 3 indexed citations
11.
Hall, Rebecca, Robert Chan, Adam Gater, et al.. (2020). Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany. Value in Health. 23(5). 632–641. 11 indexed citations
12.
Moore, Alison, et al.. (2017). Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30(3). 164–172. 9 indexed citations
13.
14.
Toublanc, Nathalie, Yun Liu, Qian Chen, et al.. (2015). Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. Clinical Drug Investigation. 35(8). 495–503. 8 indexed citations
15.
Kaneko, Sunao, et al.. (2015). A Phase III, Multicenter, Randomized, Open-label Study of Levetiracetam Monotherapy in Japanese Patients with Partial Onset Seizures. Journal of the Japan Epilepsy Society. 32(3). 519–532. 1 indexed citations
16.
Daley‐Yates, Peter T., et al.. (2013). Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol Delivered as a Combination Dry Powder from a Capsule-Based Inhaler and a Multidose Inhaler in Asthma and COPD Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 27(4). 279–289. 31 indexed citations
17.
Wielders, Pascal, et al.. (2013). A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. European Respiratory Journal. 42(4). 972–981. 41 indexed citations
18.
Jung, Ji Ye, et al.. (2008). Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. Current Medical Research and Opinion. 24(12). 3571–3582. 6 indexed citations
19.
Holmes, David R., Peter J. Fitzgerald, Sheldon Goldberg, et al.. (2000). The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial. American Heart Journal. 139(1). 23–31. 63 indexed citations
20.
Hackney, James R., C J Kahane, & Robert Chan. (1996). Activities of the new car assessment program in the United States. 1996. 1998–2018. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Milani Breakdown of academic impact, for papers by Ming‐Hsien Tsai Breakdown of academic impact, for papers by S.C. Erzurum Breakdown of academic impact, for papers by A.J. Staal-van den Brekel Breakdown of academic impact, for papers by Alexander Nixon Breakdown of academic impact, for papers by Hela Ben Nasr Breakdown of academic impact, for papers by Sema Uysal Breakdown of academic impact, for papers by Liyuan Zhang Breakdown of academic impact, for papers by Hai‐Jeon Yoon
Rankless by CCL
2026